- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D. has been appointed Executive Vice President of Operations and Chief Scientific Officer
"Mary Lynne is an exemplary leader with a strong track record of driving the growth of biotechnology companies," said Lonnie Moulder, President and Chief Executive Officer of Abraxis BioScience. "Her general management and R&D leadership experience, coupled with a deep scientific background make her an ideal addition to our executive team. We are very pleased to have this experienced executive join Abraxis as we advance our mission to enhance the lives of cancer patients throughout the world."
Dr. Hedley most recently served as Executive Vice President of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA, INC. where she had served as Executive Vice President and Chief Scientific Officer since 2005. She joined MGI PHARMA in 2004 as Senior Vice President and General Manager. Previously, Dr. Hedley co-founded ZYCOS, Inc., a biotechnology company, and held roles of progressively greater responsibility ultimately leading to her serving as the company's President and Chief Executive Officer.
Dr. Hedley's early research career consisted of two consecutive postdoctoral fellowships at Harvard University from 1989 through 1996. She earned her bachelor of science degree in Microbiology from Purdue University and her doctorate degree in Immunology from the University of Texas, Southwestern Medical Center. She is a named inventor on multiple patents in the field of immunology, and has been widely published in a variety of peer-reviewed journals. Dr. Hedley is the recipient of multiple
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.
For more information, please click here
Investors and Media Inquiries:
Abraxis BioScience, Inc.
Maili Bergman, 310-883-1300
Pondel Wilkinson Inc.
Rob Whetstone, 310-279-5963
Copyright © Abraxis BioScienceIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information